

Company	Product Status	Next Product Milestone	Financing Status	Next Financing Milestone	Success Factors	"VC" Characterization
Discera	Pre-Alpha, Working, packaged oscillator demonstrated to Customer (Qualcomm)	Customer Evaluation units to be shipped in June. Wafer packaged, multiple oscillator	Ardesta bridging operating expenses as required	Series B round; Seeking up to \$8 million; Expected close by end of Q3/early Q4	Fundraising, customer evaluations and design win	Pre-revenue; alpha development stage; hot area; mass market applications; technology and market risk; lack of market validation
Mesosystems	Shipping BT 550; Design and development of 650 started with planned availability by Q4; "wearable" dry sampler design in progress	Commercial availability of 650 by Q4 and Design completed for wearable dry sampler by Q3	\$850,000 remaining in two tranches to be funded in '03	Series B round late summer possible; pursuing strategic investment from Lockheed Martin	Launch of 650; fundraising; Homeland Security \$\$; settle Seaba lawsuit	Revenue; no mass market; Homeland Security; technology risk low; market is developing
Sensicore	Rev. B Prototype with external reference electrode (Alpha)	Working handheld with Rev B chip by Q2	Ardesta funding operating needs through bridge	Term sheet for \$10 million on \$6.1 million pre with NGEN Partners.	NGEN fundraising; Hach; handheld; customer eval's	Pre-revenue; alpha development stage; partner driven; industrial markets; mass market evolving
Sensicast	Alpha units installed and operating in Alpha trial with Gardner Museum	Beta sites in Q2 with commercial revenue by Q4; Sensimesh software architecture completed by July	Commitment to Sensicast was \$3 million with second tranche due in 2H	Series B in early '04	Move alpha trials to beta; new applications; PO's; systems integrator for ARD	Pre-revenue; alpha products; mass market applications; direct or channel sales; hot area; markets are developing not mature
Ion Optics	Customer Evaluation units (CEU) shipped to first customers for CO2 and combustible gas	Qualify and bring up commercial fab by Q3	Ardesta bridging operating needs	Term sheet with Ardesta for conversion of bridge and \$2 million of new money to close in Q3. Holding open for Side-by-Side investors or alternatives	Fundraising; commercial fab; customer evaluations; spec's of next spin	Pre-revenue; beta development stage; technology and market risks; mature markets are small; large markets are developing
Mesofuel	Working alpha prototype for Ammonia	Beta product by August 03	Closed second bridge of \$225,000	Targeting July close for Series B investment of \$3.8 million led by Murphree Venture Partners	Fundraising; alpha	pre-revenue; grant support; pre-alpha; technology and market risk; market is evolving
HandyLab	Alpha prototype with integrated sample prep and PCR	Resolve Sample prep issues by July	Cash on hand sufficient to end of year	Looking to close insider round in '03. Possibility of strategic investment by GenProbe	Agreements with Pfizer and GenProbe; sample prep issues resolved	Pre-revenue; alpha development stage; partner driven
Therafuse	Alpha prototype status with non-integrated components - reservoir, flow sensor, flow channel; microneedle, electronics	Animal (pig) studies start in May with wearability studies in June; integrated alpha prototype for pig studies	Cash on hand sufficient through the end of year	Series B ("C") to close in early Q4. Amount will vary depending on approach from \$3 to \$10 million	Animal and wearability studies; CEO; fundraising	Pre-revenue; pre-alpha development stage; technology and market risk high; large and growing market
Xcom	Pre-alpha	Alpha prototype by Q3	Financing just closed in February. Sufficient cash through Q304	Series B in mid 04. No immediate plans for fundraising	Product development	Pre-revenue; pre-alpha development stage; technology and market risk; mature and growing markets; hot area
Ardesta Radar	Alpha prototype for Ford Centennial or Windstar	Delivery of working device to Ford by end of Q2.	Funded to extent of Ford project. Next generation (2D MEMS phase shifter) to be determined	Funded to extent of Ford project. Next generation (2D MEMS phase shifter) to be determined. Amount of next round is NA pending decision on pursuit of 2D development with NASA.	IP aggregation; Ford delivery; 2D; NASA commitment	Pre-revenue; development stage; technology and market risk; market is large, but automotive
Micronics	Micronics Products - Pump System (microFlow) commercially available. One shipment to date with number of RFQ's; ABO card - Pre-production prototype in need of small development funding to complete. Development projects in various stages with Honeywell; Xtrana and Constellation	Complete design and development of ABO card with funding; delivery of next generation prototypes under Honeywell and Xtrana contracts	Ardesta and River Cities Capital filling temporary funding need with small bridge.	Company working to stabilize service business at cash breakeven and seek financing for Microcytometry spinout. No plans to raise money for Micronics at this time.	Services business stabilized; systems platform success; strategic focus on applications area (microcytometry)	Services revenue (platform); beta products; questionable market applications; little technology risk; strong IP
Phoenix	Working handheld prototype for "poke and fill"	Next product milestones subject to capital raise - integration of cartridge and analysis capabilities	Cash on hand sufficient through the end of Q3.	Series B round in Q4 or Strategic Sale	Strategic investor/acquiror	pre-revenue; alpha; technology risk low; market risk moderate; partner driven
Sarcon	Completed working prototypes performing below spec, but at 300-500 mk. CEU's demonstrated images at SPIE show	CMOS redesign to achieve 100 mK performance by year end	Cash on hand sufficient for next month or so. No new funding from Ardesta or Noro Mosely pending strategic discussions	Company is seeking strategic investors, acquirors or development \$\$\$. Target for Letters of Intent set for June '03	Strategic partners/investors; new CMOS; new CEU's	Pre-revenue; development; technology risk; mitigated market risk; markets mature and growing